The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIX.i

Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

Publications

Yang ZY, Liu L, Mao C, Wu XY, Huang YF, Hu XF, Tang JL

Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.

The Cochrane database of systematic reviews 2014 Nov 17;;CD009948 — 2014 Nov 17 — CD009948

Keating K, Walko C, Stephenson B, O'Neil BH, Weiss J

Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2014 Dec;20;409-16 — 2014 Dec — 409-16

Hopps S, Medina P, Pant S, Webb R, Moorman M, Borders E

Cetuximab hypersensitivity infusion reactions: Incidence and risk factors.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2013 Sep;19;222-7 — 2013 Sep — 222-7

Song X, Long SR, Barber B, Kassed CA, Healey M, Jones C, Zhao Z

Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer.

Current clinical pharmacology 2012 Feb 01;7;56-65 — 2012 Feb 01 — 56-65

Leonard B, Taylor D

Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression.

Journal of psychopharmacology (Oxford, England) 2010 Aug;24;1143-52 — 2010 Aug — 1143-52

O'Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, Goldberg RM

High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Aug 20;25;3644-8 — 2007 Aug 20 — 3644-8